World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
112
Citations
51124
World Ranking
5115
National Ranking
2765

Robert Elashoff publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert Elashoff sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 375 publications — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert Elashoff D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert Elashoff sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 112 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1972 - Fellow of the American Association for the Advancement of Science (AAAS)
  • 1970 - Fellow of the American Statistical Association (ASA)

Overview

Robert Elashoff was affiliated with the University of California, Los Angeles in the United States. Their research primarily focused on the fields of Medicine and Mathematics, with a notable concentration on Statistics and Probability among other medical subfields.

Their work spanned several subfields including Statistics and Probability, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Epidemiology, and Health, Toxicology and Mutagenesis. The main topics explored in their publications covered Systemic Sclerosis and Related Diseases, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Inflammatory Myopathies and Dermatomyositis, Statistical Methods and Inference, Statistical Methods in Clinical Trials, Statistical Distribution Estimation and Applications, and Air Quality and Health Impacts.

Some of the recent papers attributed to their research include:

  • Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease (2020), Arthritis & Rheumatology
  • Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II (2020), ACR Open Rheumatology
  • A flexible joint model for multiple longitudinal biomarkers and a time-to-event outcome: With applications to dynamic prediction using highly correlated biomarkers (2021), Biometrical Journal
  • Peripheral Blood Flow Changes to Cutaneous and Muscular Beds in Response to Acute Hookah Smoking (2020), The American Journal of Cardiology
  • The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis (2020), Seminars in Arthritis and Rheumatism

Frequent co-authors throughout their career included:

  • Donald P. Tashkin
  • Shervin Assassi
  • Ning Li
  • Elizabeth R. Volkmann
  • Michael D. Roth

Their contributions appeared in venues such as Arthritis & Rheumatology, ACR Open Rheumatology, Biometrical Journal, Seminars in Arthritis and Rheumatism, and The American Journal of Cardiology.

During their career, Robert Elashoff received recognition as a Fellow of the American Association for the Advancement of Science (AAAS) in 1972 and a Fellow of the American Statistical Association (ASA) in 1970.

Best Publications

  • Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis

    William G. Goodman;Jonathan Goldin;Beatriz D. Kuizon;Chun Yoon

  • Sentinel-node biopsy or nodal observation in melanoma

    Donald L. Morton;John F. Thompson;Alistair J. Cochran;Nicola Mozzillo

  • Cyclophosphamide versus placebo in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Jonathan Goldin

  • Malignant Melanoma: Effects of an Early Structured Psychiatric Intervention, Coping, and Affective State on Recurrence and Survival 6 Years Later

    Fawzy I. Fawzy;Nancy W. Fawzy;Christine S. Hyun;Robert Elashoff

  • Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma

    D. L. Morton;J. F. Thompson;A. J. Cochran;N. Mozzillo

  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

    Mark B. Faries;John F. Thompson;Alistair J. Cochran;Robert H. Andtbacka

  • Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

    Michael Elashoff;Aleksey V. Matveyenko;Belinda Gier;Robert Elashoff

  • Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study

    Rowan T. Chlebowski;George L. Blackburn;Cynthia A. Thomson;Daniel W. Nixon

  • Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma: A Multicenter Trial

    Donald L. Morton;John F. Thompson;Richard Essner;Robert Elashoff

  • A structured psychiatric intervention for cancer patients: I. Changes over time in methods of coping and affective disturbance.

    Fawzy I. Fawzy;Norman Cousins;Nancy W. Fawzy;Margaret E. Kemeny

  • Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

    Donald P. Tashkin;Michael D. Roth;Philip J. Clements;Daniel E. Furst

  • Statistical estimations in pharmacokinetics

    Harold G. Boxenbaum;Sidney Riegelman;Robert M. Elashoff

  • Sentinel node biopsy for early-stage melanoma - Accuracy and morbidity in MSLT-I, an international multicenter trial

    Donald L. Morton;Alistair J. Cochran;John F. Thompson;Robert Elashoff

  • Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement

    David Heber;Ian Yip;Judith M Ashley;David A Elashoff

  • A Structured Psychiatric Intervention for Cancer Patients: II. Changes Over Time in Immunological Measures

    Fawzy I. Fawzy;Margaret E. Kemeny;Nancy W. Fawzy;Robert Elashoff

  • Patterns of care related to age of breast cancer patients

    Sheldon Greenfield;Dolores M. Blanco;Robert M. Elashoff;Patricia A. Ganz

  • Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer

    Allan J. Pantuck;John T. Leppert;Nazy Zomorodian;William Aronson

  • PRIMARY CYTOREDUCTIVE SURGERY FOR EPITHELIAL OVARIAN CANCER

    N F Hacker;J S Berek;L D Lagasse;R K Nieberg

  • Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Michael D. Roth

  • Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

    Albert Lai;Anh Tran;Phioanh L. Nghiemphu;Whitney B. Pope

Frequent Co-Authors

He-Jing Wang
He-Jing Wang University of California, Los Angeles
Donald P. Tashkin
Donald P. Tashkin University of California, Los Angeles
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Dinesh Khanna
Dinesh Khanna University of Michigan–Ann Arbor
Donald L. Morton
Donald L. Morton Saint John's Health Center
John A. Belperio
John A. Belperio University of California, Los Angeles
Philip J. Clements
Philip J. Clements University of California, Los Angeles
Jonathan G. Goldin
Jonathan G. Goldin University of California, Los Angeles
Joseph P. Lynch
Joseph P. Lynch University of California, Los Angeles
David Heber
David Heber University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical and healthcare careers in the USA goes beyond traditional medical school. There are diverse online degree options for those interested in nursing, advanced practice, or fast-entry programs.

For registered nurses looking to advance their education, rn to bsn online without clinicals programs offer the flexibility to earn a bachelor's degree without additional hands-on requirements. This helps working nurses enhance their credentials while balancing job demands.

If you're interested in doctoral-level nursing practice, consider exploring the shortest dnp programs online for a faster path to leadership roles. For those prioritizing ease and flexibility, there are also online dnp programs designed to accommodate busy professionals.

Those who want to enter the nursing field quickly can benefit from an accelerated Licensed Practical Nurse option, such as a 9 month lpn program. These programs provide a direct and efficient way to launch a healthcare career.

Whether you’re pursuing advanced roles or looking for rapid entry into healthcare, these online pathways offer flexible solutions tailored to a variety of goals.

Best Scientists Citing Robert Elashoff

Recently Published Articles